Needle-Free Injection Systems Market Overview:
Global Needle-Free Injection Systems Market was valued at $8,166 million in 2016, and is estimated to reach $23,116 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Needle-free injection systems are used to administer liquid formulations, drugs, and vaccines into patients without piercing the skin with a conventional needle. The demand for these systems has increased considerably in the recent years as they improve immune response to vaccines, eliminate risks of needles, and reduce healthcare costs. However, lack of skilled professionals and the restricted use of needle-free injection systems for intravenous administration impede the market growth.
Rise in Diabetic Population
Rise in prevalence of diabetes raises the demand for needle-free insulin delivery devices. According to the Centers for Disease Control and Prevention, in 2015, approximately 30.3 million people or 9.4% of the total population of the U.S. suffered with diabetes. In addition, according to the Diabetes UK, in 2016, approximately 3.6 million people were diagnosed with diabetes in the UK. Hence, increase in diabetics is expected to have a positive impact on the market.
Growth in Asia-Pacific
Asia-Pacific offers lucrative opportunities for the market growth, due to its high population base and growth in awareness about the benefits of needle-free injections and their application in treatment of cancer, diabetes, and other infectious diseases.
Benefits of Needle-Free Injection Systems
Needle-free injection systems ensure faster drug delivery and better reproducibility as compared to invasive drug delivery systems. In addition, needle-free injection systems also eliminate the needle phobia and enable self-administration of drugs.
Global Needle-Free Injection Systems: Market Segmentation
The global needle free injection system market is segmented on the basis of product, source of power, type, usability, site of delivery, application, end user, and region. Based on product, the market is classified into fillable and prefilled needle-free injection systems. By source of power, it is divided into spring-based and gas-propelled/air forced injector systems. According to type, it is segmented into liquid-based, projectile/depot-based, and powder-based. By usability, it is bifurcated into disposable and reusable needle-free injectors. On the basis of site of delivery, the market is categorized into subcutaneous, intramuscular, and intradermal injectors. Based on application, it is segmented into vaccine delivery, insulin delivery, pain management, and others. According to the end user, the market is classified into hospitals & clinics, home care settings, research laboratories, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key companies operating in the market include Antares Pharma, Inc., PharmaJet, PenJet Corporation, Medical International Technology, Inc., INJEX Pharma AG, Crossject needle-free injection systems, National Medical Products Inc., Valeritas, Inc., and European Pharma Group.
South Africa Needle-Free Injection Systems Market, 2016-2023 ($Million)
Key Benefits:
The study provides an in-depth analysis of the global needle-free injection systems market, with current trends and future estimations, to elucidate the imminent investment pockets.
Quantitative analysis from 2016 to 2023 of all geographical regions is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Needle-Free Injection Systems Market Key Segments:
By Product
- Fillable
- Prefilled
By Source of Power
- Spring-based Injector Systems
- Gas Propelled/Air Forced Injector Systems
By Type
- Liquid-based
- Projectile/Depot-based
- Powder-based
By Usability
- Disposable
- Reusable
By Site of Delivery
- Subcutaneous Injectors
- Intramuscular Injectors
- Intradermal Injectors
By Application
- Vaccine Delivery
- Insulin Delivery
- Pain Management
- Others
By End User
- Hospitals & Clinics
- Home Care Settings
- Research Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Needle-Free Injection Systems Market Report Highlights
| Aspects | Details |
 By PRODUCT |
|
 By SOURCE OF POWER |
|
 By TYPE |
|
 By SITE OF DELIVERY |
|
 By USABILITY |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | THE EUROPEAN PHARMA GROUP, MEDICAL INTERNATIONAL TECHNOLOGY, INC., ANTARES PHARMA, INC., VALERITAS HOLDINGS, INC., NATIONAL MEDICAL PRODUCTS, INC., PHARMAJET, CROSSJECT NEEDLE FREE INJECTION SYSTEMS, INJEX PHARMA AG |
Analyst Review
Globally, chronic disorders, such as diabetes, typhoid, and Hepatitis A, constitute a major proportion of health and economic burden. Moreover, increase in incidence of needle-stick injuries leads to high risk of exposure to blood-borne pathogens such as HIV and hepatitis B and/or C. Hence, the adoption of needle-free syringes is vital for a safe and effective method of administration of vaccines and drugs into the patient.
Surge in the incidence of disorders, such as typhoid, and reduction in healthcare costs due to the use of needle-free injectors and elimination of risk of needles have led to increase in demand for these systems. In addition, benefits of needle-free injection systems, such as feasible self-administration of drugs, further fuels the market growth.
Asia-Pacific, especially emerging countries, such as China and India, possesses high growth potential due to rapid increase in geriatric population and rise in incidence of chronic diseases such as diabetes.
Loading Table Of Content...
